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Epidermal growth factor receptor (EGFR) is overexpressed in head and neck squamous cell carcinoma (HNSCC)
where it has been shown to promote tumor cell invasion upon phosphorylation. One mechanism by which EGFR
promotes tumor progression is by activating signal cascades that lead to loss of E-cadherin, a transmembrane
glycoprotein of the cell-cell adherence junctions; however mediators of these signaling cascades are not fully
understood. One such mediator, RhoC, is activated upon a number of external stimuli, such as epidermal growth
factor (EGF), but its role as amediator of EGF-stimulatedmigration and invasion has not been elucidated inHNSCC. In
the present study, we investigate the role of RhoC as amediator of EGF-stimulatedmigration and invasion in HNSCC.
We show that upon EGF stimulation, EGFR and RhoCwere strongly activated in HNSCC. This resulted in activation of
the phosphatidylinositol 3-Kinase Akt pathway (PI3K-Akt), phosphorylation of GSK-3β at the Ser9 residue, and
subsequent down regulation of E-cadherin cell surface expression resulting in increased tumor cell invasion.
Knockdown of RhoC restored E-cadherin expression and inhibited EGF-stimulatedmigration and invasion. This is the
first report in HNSCC demonstrating the role RhoC plays in mediating EGF-stimulated migration and invasion by
down-regulating the PI3K-Akt pathway and E-cadherin expression. RhoCmay serve as a treatment target for HNSCC.
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According to theWorld Health Organization (WHO), head and neck
squamous cell carcinoma (HNSCC) is amongst the most prevalent
cancers worldwide, consistently ranking in the top twelve of most
common cancers. It is estimated that in 2014 there will be over
42,000 new cases of oropharyneal cancer in the United States alone,
which will account for more than 8000 deaths [1]. Unfortunately,
despite advancements in chemotherapy, radiation therapy and
surgical approaches, the survival rates have not improved for decades,
most likely due to identification of most of these cancers at a very late
stage when tumors have already undergone locoregional and distant
spread. This is further complicated by the fact that aggressive
treatments are selected on the basis of tumor size and spread rather
than on the biology of individual lesions. However, two tumors that
receive the same treatment may vary dramatically in biologic
behavior. Therefore, characterization of signaling cascades that are
responsible for tumor development, invasion and metastasis in
HNSCC will help to identify aggressive tumors earlier in the disease
process and will aid in the development of new treatment approaches.Studies have shown that aberrant activation of Rho family of
GTPases, members of the Ras homology protein family, promotes
uncontrolled cellular proliferation as well as increases the invasive and
metastatic potential of tumor cells [2–4]. Specifically, Rho GTPases
have been shown to cause tumorigenic transformation of rodent
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breast cancer cell invasion [8] and melanoma cell metastatic growth
[9]. Rho accomplishes this by shuttling between inactive guanine
diphosphate (GDP) and active GTP-bound forms. It is the active
GTP-bound form that triggers a cell response.
Of the Rho family members (RhoA, RhoB, RhoC, Rac1, Rac2,
Rac3, and CDC42), RhoC is increasingly being implicated in a variety
of malignant tumor types, including HNSCC. Studies have shown
that RhoC overexpression is linked to metastatic behavior in HNSCC
where selective RhoC inhibition markedly decreases cell motility and
invasion in vitro and in vivo [10]. Additionally, Islam et al., 2014,
recently demonstrated that RhoC plays an important role in signal
transduction and activation of transcription 3 (STAT3) phosphory-
lation and the activation of core cancer stem cell transcription factors
[11]. Despite the emerging evidence establishing RhoC as a key player
in HNSCC invasion and metastasis, little is known about the
intracellular signaling cascades that lead to RhoC activation and the
subsequent effects on downstream signaling molecules.
In order for a tumor cell to invade surrounding tissues leading to
metastatic disease, it must acquire motile and invasive characteristics
—namely, these cells undergo transition to a more mesenchymal,
fibroblast-like morphology where cell-to-cell contacts are disrupted.
This process is collectively referred to as epithelial-to-mesenchymal
transition (EMT). Epithelial cadherin (E-cadherin) is a transmem-
brane glycoprotein of the cell-cell adhesion transmembrane molecule
and its down-regulation leading to disruption of adherence junctions
has been shown to contribute to the EMT process. Furthermore, E-
cadherin plays important roles in cellular signal transduction in
collaboration with receptor tyrosine kinases such as the Epidermal
Growth Factor Receptor (EGFR), which is highly expressed in
HNSCC and is inversely correlated with patient survival [12,13].
Studies have shown that EGFR phosphorylation, subsequent to
Epidermal Growth Factor (EGF) binding, can lead to transcriptional
regulation of E-cadherin via the phosphatidylinositol 3-kinase/Akt/
GSK-3β (PI3K/Akt/GSK3β) pathway. The PI3K/Akt/GSK3β sig-
naling cascade is involved in the development and progression of
HNSCC and plays a role in tumor resistance to radiotherapy and
chemotherapy [14,15]. E-cadherin transcription is regulated by
multiple processes, including hypermethylation and repression of
promoter activity of the Snail superfamily of zinc-finger transcription
factors, Snail and Slug. Growing evidence suggests that the epidermal
growth factor receptor family and its downstream signaling pathways,
such as PI3K/Akt/GSK3β, up-regulate Snail leading to underexpres-
sion of E-cadherin [15].
In this study, we explored the role RhoC plays in EGFR/PI3K/Akt/
GSK3β signaling and the cell–cell adhesion function of E-cadherin.
We demonstrate that RhoC mediates EGFR/PI3K/Akt/GSK3β
signaling inHNSCC to reduce E-cadherin expression, thus promoting
a more invasive phenotype. To the best of our knowledge, the role of
RhoC in EGFR/PI3K/Akt/GSK3β signaling pathways has not yet
been reported in HNSCC. Our findings add to the growing evidence
supporting the promise of RhoC as a prognostic marker and potential
therapeutic target for HNSCC.
Materials and Methods
Cell Culture
Human oral SCC cell lines were grown in Dulbecco’s modified
Eagle’s medium/F-12 (DMEM/F-12, Thermo scientific) containing2.5 mM L-Glutamine, 15 mM HEPES buffer, 10% fetal bovine
serum, 100 μg/ml penicillin, 100 μg/ml streptomysin. The primary
human oral keritinocyte cell line (HOK, Science cell research
Laboratories) was maintained in Oral Keratinocyte Medium (OKM)
containing oral keratinocyte growth supplementation (OKGS) and
penicillin/streptomysin (Science cell research Laboratories).
Western Blot Analysis
Cells with or without treatment with Epidermal Growth Factor
(EGF) (Sigma Aldrich) were washed with ice-cold phosphate-
buffered saline and lysed in RIPA buffer (25mM Tris.HCl pH 7.6,
150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS)
containing Halt protease inhibitor cocktail (Thermo scientific). For
phospho – antibodies the lysis buffer was supplemented with Halt
phosphotase inhibitor cocktail (Thermo scientific). Cell lysates were
scraped into Microfuge tubes and left for 20 min with occasional
vortexing, and was pelleted by centrifugation at 12,000 rpm for
20 min at 4 °C. The supernatant was collected, and protein content
was measured by the Coomassie (Bradford) Protein Assay Kit
(Thermo scientific). Equal amount of protein (25 μg) were
electrophoresed on 8 or 12% SDS-PAGE gels and transferred to
PVDF membranes (BioRad). The membranes were blocked with 5%
nonfat milk or with 3% BSA in Tris - buffered saline containing 0.1%
Tween-20 (TBS-T) (Fisher) for 1h at room temperature (RT) to
block nonspecific binding. Membranes were incubated with the
primary antibody for 2h at RT or overnight at 4 °C. Primary antibody
concentrations were as follows: EGF Receptor (D38B1) XP Rabbit
monoclonal antibody (1:1000), Phospho - EGF Receptor (Tyr992)
antibody (1:500), Phospho - EGF Receptor (Tyr1068) (D7A5) XP
Rabbit monoclonal antibody (1:1000), RhoC (D40E4) Rabbit
monoclonal antibody (1:1000), RhoA (67B9) Rabbit monoclonal
antibody (1:1000), E-Cadherin (24E10) Rabbit monoclonal anti-
body (1:5000), Phospho-GSK-3β (ser9) (5B3) Rabbit monoclonal
antibody (1:2000), GSK-3β (27C10) Rabbit monoclonal antibody
(1:2000), phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204)
(D13.14.4E) XP Rabbit monoclonal antibody (1:2000), p44/42
MAPK (ERK1/2) (Thr202/Tyr204) (137F5) Rabbit monoclonal
antibody (1:2000), Phospho-Akt (Ser473) (D9E) XP Rabbit
monoclonal antibody (1:2000), Akt (pan) (C67E7) Rabbit mono-
clonal antibody (1:2000), Snail (C15D3) Rabbit monoclonal
antibody (1:500). Membranes were washed in TBS-T. Anti-rabbit
IgG, HRP-linked antibody used as a secondary antibody to detect
primary antibodies. Visualization of immunoreactive proteins
was accomplished by superSignal West pico Chemiluminescent
substrate (Thermo Scientific) and exposure to film or VersaDoc
(Biorad). For Akt inhibition experiments, UM-SCC-6 cells were pre-
treated with the AKT inhibitor, Ly294002, for 30 minutes
followed by stimulation with EGF for 5 minutes. Densitometric
analysis was performed and densitometric units (DU) are presented
for each immunoblot.
Rho Pull-Down Assay
Cells were treated with EGF for 5 minutes to 2 hours. Then GTP
bound Rho proteins were pulled down using a rhotekin binding and
detection kit (Thermo Scientific) according tomanufacturer’s instruction.
Small Interfering RNA (siRNA) Transfection
To knock down RhoC, cells were transfected with ON-Targetplus
SMARTpool RhoC (50 nM) (Dharmacon Reseach, Inc) using
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Figure 1. EGFR is expressed and phosphorylated upon EGF binding in HNSCC cell lines. (A) Whole cell lysate of HOK, UM-SCC-(1,5,6,10B,
17B), and SCC-(0, 1483) were separated by PAGE and blotted with EGFR antibodies. The same membrane was subsequently blotted with
GAPDH antibody to verify equivalency of loading. DU = densitometic units. (B) HOK and UM-SCC-5, -6, and -10B cells were analyzed for
endogenous expression of phospho-EGFR at Tyr992 and phospho-EGFR at Tyr1068. Total EGFR and GAPDHwere used as loading controls.
(C) Dose response of EGF-mediated phosphorylation of EGFR.HOK,UM-SCC-6, and -10Bcellswere stimulatedwith 1 to 100 ng/ml of EGF for
5 min and then were analyzed for EGFR-Tyr 992 phosphorylation.
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antibiotics. The siCONTROL Non-Targetingpool siRNA (Dhama-
con) was used as a transfection control. Western Blot samples were
prepared 72 h after siRNA transfection.
Wound Healing Assay
Cell migration was assessed by the ability of cells to migrate into
a cell-free area. Once the cells reached confluence, the medium was
changed to FBS free medium for overnight starvation. The
monolayers were then wounded by using a 200ul pipet tip and
washed with PBS twice. After washing, the cells were incubated in
the medium with or without EGF for the desired time period. The
migration was observed under the microscope (NiKON Eclipse
TS100, Japan). The images were taken by using cyberlink
PowerDirector 10 softwear at 4× magnification. The width of
the scratches was observed and measured using Image J software.
The relative distance was calculated as a mean width of the
cell scratch.Invasion Assay
Cell invasion was measured by using QCM 24-well Collagen-
Based Cell Invasion Assay (Millipore Corporation). siRNA trans-
fected cells were treated according to manufacturer’s instruction. Cells
were stimulated with EGF for 48h. The results were read by using a
microplate reader at the 562nM wavelength.
Immunofluorescent Staining
Transfected cells were seeded into 35mm glass bottom culture
dishes (MatTek corporation). When the cells reached 70%
confluence, they were starved and cultured in the medium with or
without EGF for the desired time. Cells were then washed once with
phosphate-buffered saline (PBS) and fixed with HistoChoiceMB
(Molecular Biology) tissue fixative (Amresco) for 20 minutes at RT.
Cells were washed with PBS three times and permeabilized with 0.5%
Triton X-100 in PBS for 10 minutes at RT. After washing cells twice
with PBS, the cells were blocked with 5% BSA in PBS for 1h at RT
and incubated with purified mouse anti-E-Cadherin mAb (BD
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Figure 2. EGFR phosphorylation at Tyr992 activates the PI3-kinase pathway and up-regulates Snail protein expression. (A) Snail expression in
HOK and UM-SCC-6 was examined via immunoblot analysis. (B) Snail expression is up-regulated following EGF stimulation. UM-SCC-6 cells
were stimulated with 100 ng/ml of EGF for varying durations from 1 to 24 hours. Whole cell lysates were blotted to detect Snail expression.
GAPDH was used as loading control. (C) ERK, GSK-3βser9 and AKT are phosphorylated following EGF stimulation. UM-SCC-6 cells were
stimulated with 100 ng/ml EGF for 5 min to 2 h. Whole cell lysates were blotted with phospho-ERK, phospho-GSK-3βser9 and phospho-AKT
antibodies followed by total ERK, AKT and GSK-3βser9 antibodies, respectively. (D) EGFR phosphorylates GSK-3βser9 via the PI3-kinase
pathway. UM-SCC-6 cells were pre- incubated for 1 hour with 25 μM of LY294002 or DMSO as vehicle control followed by 100ng/ml EGF
stimulation. Akt andGSK-3βser9 activationwere evaluated by immunoblot analysis ofwhole cell lysateswith phospho-Akt and phosphor-GSK-
3βser9, respectively. The membrane was subsequently blotted with total Akt, GSK-3βser9, and GAPDH antibodies as loading controls.
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Fluor546-labeled donkey anti-mouse IgG (Invitrogen) was used as a
secondary antibody (1:500). Finally, the cells were mounted with
Vectashield mounting medium for fluorescence with DAPI (Vector
Laboratories, Inc.) and were examined using a confocal microscope
(Nikon TE2000-U).
Statistical Analysis
Student’s t test or paired t test was used to evaluate the significance
of differences between two groups. The differences were considered
statistically significant if P b .05.
Results
EGFR is Highly Expressed in HNSCC and is Robustly
Phosphorylated upon EGF Binding
The importance of EGFR expression, phosphorylation, and
activation of downstream effectors has been well characterized in avariety of tumor types [16–19], but the role of small GTPases in
mediating these important signaling cascades is not as clear. In this
study, initial experiments sought to confirm EGFR expression and
signaling in non-malignant human oral keratinocytes (HOK) and in a
panel of well-characterized HNSCC cell lines: UM-SCC-1, UM-
SCC-5, UM-SCC-6, UM-SCC-10B, UM-SCC-17B, SCC-0, and
SCC-1483. As expected, EGFR protein levels were variably expressed
across all cell lines, with the highest level of expression seen in
UM-SCC-6 and UM-SCC-10B cells (Figure 1A). Of the cell lines
tested, UM-SCC-6 cells were chosen for subsequent experiments
based on the observation that 1) total EGFR was highly expressed in
these cells; 2) endogenous EGFR phosphorylation was relatively low
in the absence of exogenous epidermal growth factor (EGF)
stimulation (Figure 1B); and 3) RhoC protein was highly expressed
in these cells (Figure 3A).
We next determined whether we could activate EGFR upon
treatment with increasing concentrations of EGF (0.1–100 ng/ml).
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Figure 3. RhoC is expressed in HNSCC and is activated by EGFR. (A) Whole cell lysate of HOK, UM-SCC-(1, 5, 6, 10B, 17B), and SCC-(0,
1483) were separated by PAGE and blotted with RhoA and RhoC antibodies. GAPDHwas used as loading control. (B) HOK and UM-SCC-6
cells were stimulated with 100 ng/ml of EGF for varying durations from 5minutes to 2 hours and RhoA and RhoC activation was evaluated
by a pull down assay. Total RhoA, RhoC and GAPDH were used as loading controls. Active, GTP-bound Rho was quantified by
densitometry and normalized to total normalized Rho with respect to GAPDH.
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transition from an inactive monomeric form to active homodimer and
heterodimers. EGFR dimerization stimulates its intrinsic intracellular
protein-tyrosine kinase activity and autophosphorylation of several
tyrosine residues in the C-terminal domain of EGFR occurs [20].
EGFR phosphotyrosine residues Tyr992 and Tyr1068 were selected
for investigation based on their known association with tumor
progression. EGFR autophosphorylation elicits downstream activa-
tion and signaling by several other proteins that associate with the
phosphorylated tyrosines through their own phosphotyrosine-
binding SH2 domains [20]. Of the possible tyrosine residues
phosphorylated upon EGF binding, we chose Tyr992 for further
investigation due to its known effects on increasing the duration of
interaction with effector molecules, its low endogenous phosphory-
lation status in non-malignant cells (Figure 1B, top panel), its
described role in linking EGFR to a diversity of downstream signaling
pathways, including the PI3K pathway, and its effects on cytoskeletal
remodeling, suggesting a potential role in tumor progression [21]. Inthe presence of 100 ng/ml of EGF, EGFR was strongly phosphor-
ylated at residue Tyr992 in HOK, UM-SCC-6, and UM-SCC-10B
cells, however only the HNSCC cells demonstrated Tyr992
phosphorylation at concentrations as low as 1.0 ng/ml (Figure 1C).
This finding is consistent with other studies where EGFR
phosphorylation was determined to be more sensitive to lower
concentrations of EGF depending on differential phosphotyrosine
residue activation and cell type [22].
EGFR Phosphorylation at Tyr992 Activates the PI3K Pathway
and Up-regulates Snail Protein Expression
E-cadherin is frequently lost during advanced stages of epithelial
cancer progression due to up-regulation of the transcription factor,
Snail, following EGFR activation. Increased Snail expression has been
correlated with HNSCC invasion and local recurrence following
therapy, which is consistent with its role in diminishing cell-to-cell
contact by binding to the E-cadherin promoter and repressing
transcription [23]. In agreement with these findings, we observed
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Figure 4. RhoC knock-down decreases EGF-stimulated Akt and GSK-3βser9 phosphorylation. (A) Expression of RhoC in HNSCC cells
transfected with siRhoC. Plasmid expressing either control siRNA (siNon-target) or RhoC-specific siRNA (siRhoC) was transfected into
UM-SCC-6 cells as described in the Materials and Methods. The cells were then simulated with 100 ng/ml EGF. RhoA and RhoC
expression were confirmed by immunoblot analysis with GAPDH serving as a loading control. (B) At 72 hours following transfection with
either siNon-target or siRhoC, UM-SCC-6 cells were stimulated with 100 ng/ml EGF or vehicle control for 5 minutes. Whole cell lysates
were then blotted with phospho-ERK, phospho-GSK-3βser9 and phospho-AKT antibodies followed by total ERK, AKT and GSK-3βser9
antibodies, respectively.
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HOK cells (Figure 2A). Furthermore, Snail expression was greatly
stabilized in as little as three hours following EGF stimulation in UM-
SCC-6 cells (Figure 2B). Previous studies in other tumor types have
shown that Snail up-regulation and subsequent E-cadherin loss is
mediated by glycogen synthase kinase-3β phosphorylation at Ser9
(GSK-3β ser9), which is a well-known downstream effector of the
PI3K/Akt pathway and several other pathways (a notable example
being the mitogen-activated protein kinase (MAPK) pathway), and
has been shown to stabilize Snail leading to its localization into the
nucleus [23]. Indeed, we observed phosphorylation of Akt and GSK-
3β ser9 in UM-SCC-6 cells at 5 minutes following treatment with
EGF (Figure 2C). Given that a number of other pathways can also
phosphorylate GSK-3β ser9, we next set out to confirm that GSK-
3β ser9 is indeed phosphorylated by an EGFR/PI3K/Akt mechanism
in the UM-SCC-6 cells. To do so, we measured EGF-stimulated
GSK-3β ser9 phosphorylation in the presence or absence of a well-
established PI3K pathway inhibitor, Ly294002. As expected, GSK-
3β ser9 phosphorylation was enhanced following stimulation with
100ng/ml concentration of EGF in the absence of Ly294002 but was
reduced by over 40% upon inhibition of the PI3-kinase pathway with
Ly294002 (Figure 2D), confirming the important role the PI3K/Akt
pathway plays in GSK-3β ser9 signaling in these cells.
RhoC is Expressed inHNSCC and is Activated by EGFR Signaling
RhoC has been linked to increased metastatic behavior in a variety
of tumor types, but its specific role in cell signaling pathways that lead
to tumor progression is poorly understood. Building on the fact that
Rho GTPases have been previously shown to activate PI3K/Akt in
other cell systems, we hypothesized that perhaps RhoC plays an
important role in linking EGFR activation to PI3K activation, leading
to E-cadherin loss in HNSCC. To test this hypothesis, we first
determined the level of RhoC expression (as well as RhoA expressionfor comparison) in the same panel of HNSCC cell lines used in our
EGFR expression studies. We then assessed RhoC activation status
following EGF treatment. Protein expression was confirmed using
isoform-specific Rho antibodies. As seen in Figure 3A, primary and
malignant kertinocytes express RhoC and RhoA at variable levels,
however when compared with the corresponding GAPDH signals
that served as loading controls, it is apparent that UM-SCC-6 is one
of the strongest expressers of RhoC and one of the weakest expressers
of RhoA. The effect of EGF on Rho-GTP was analyzed using a
previously described Rho pull-down assay, which only binds the
active form of Rho proteins. Interestingly, EGF stimulation increased
the level of active RhoA in both primary keratinocytes and UM-SCC-
6 cells; however, the active form of RhoC was only increased in UM-
SCC-6 cells following EGF stimulation (Figure 3, B and C). These
results suggest different roles for RhoA and RhoC in normal and
cancer cells.
RhoC Knock-Down Decreases EGF-stimulated Akt and
GSK-3β ser9 Phosphorylation
Since RhoC was significantly up-regulated by EGF in UM-SCC-6
cells, we next knocked down RhoC expression in the same cells using
siRNA gene silencing techniques and then looked at the resultant
downstream effects on the PI3K pathway (and the MAPK pathway
for comparison). First, we confirmed the specificity of RhoC
knockdown by comparing immunoblot expression of RhoC versus
RhoA following siRNA transfection. As seen in Figure 4A, following
siRNA transfection RhoC expression was significantly reduced to
almost undetectable levels whereas RhoA protein expression remained
unaffected, confirming the specificity of the siRNAs for RhoC. Next,
we determined the effects of RhoC knock-down on EGF-stimulated
Akt and GSK-3β ser9phosphorylation. Knocking down RhoC de-
creased EGF-induced phosphorylation of Akt and GSK-3β ser9 by
31% and 34%, respectively (Figure 4B), but had no effect on the
- + - + EGF
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Figure 5. Effects of RhoC knock-down on E-cadherin expression. (A and B) UM-SCC-6 cells were stimulated for 6 days with 100 ng/ ml EGF
followedby immunoblot analysis of E-cadherin expression in non-transfected and siRhoCor control-transfected siNon-targetUM-SCC-6 cells.
GAPDH served as a loading control. (C) Subcellular localizations E-cadherin was examined using immunofluorescence analysis. Of note,
knocking down RhoC expression caused reduced E-cadherin membrane localization. Images were obtained at 40× magnification.
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regulated kinase (ERK; Figure 4B), suggesting a greater role for
RhoC as a mediator in the EGFR-PI3K signaling cascade as compared
to the EGFR-MAPK pathway.
RhoC knock-down rescues E-cadherin loss and inhibits cell
migration and invasion
As described above, RhoC serves as a mediator of the EGFR/PI3k/
Akt/GSK-3β ser9 signaling cascade, but what is the biological
significance of this newly described role for RhoC in HNSCC? To
answer this question we evaluated E-cadherin expression and
determined the effects on migration and invasion in RhoC knock-
down cells. As expected, E-cadherin expression was reduced in the
UM-SCC-6 parent cell line (Figure 5A) and in cells expressing control
siRNA (siNon-target) (Figure 5B) six days following EGF stimula-
tion, whereas cells expressing RhoC-specific siRNA (siRhoC) showed
no such E-cadherin loss (Figure 5B). Similarly, confocal microscopicanalysis revealed that RhoC knock-down cells maintained a greater
degree of cell-to-cell contact and E-cadherin membrane localization
(Figure 5C) and were significantly less invasive (Figure 6A, P ≤ .05)
and motile (Figure 6B, P ≤ .0001) in comparison to their siNon-
target counterparts.
Discussion
The three Rho GTPases of higher vertebrates, RhoA, B, and C, share
85% amino acid sequence identity [24]. Different Rho proteins are not
functionally redundant in the cell but play different roles in cell
physiology [25,26]. Of the three Rho GTPases, RhoC is most
convincingly linked with cancer metastasis. Association between RhoC
and tumor progression has been described in a variety of tumor types,
including breast cancer [27], non-small cell lung carcinoma [28], colon
carcinoma [29],malignantmelanoma [2], and hepatocellular carcinoma
[30]. In HNSCC, RhoC overexpression has been linked to metastatic
behavior inHNSCC [10]. The role of RhoA in tumor progression is not
* p. < 0.05
A 
0 h
72 h
CohRistegrat-noNis
B
Figure 6. RhoC knock-down inhibits EGF-stimulated cell migration and invasion. Scratch assay and transwell chamber assay were used to
compare the migratory and invasive capabilities, respectively, of siRhoC or control-transfected siNon-target UM-SCC-6 cells. (A) The
effect of RhoC knockdown on cell invasion was investigated by comparing the invasion index of siRhoC-transfected cells against siNon-
target controls, where siNon-target invasion was set at 100% ( P b .05). (B) Knocking down RhoC with siRNA prevented migration of cells
to the scratched area as compared to siNon-target control. The width of the scratches was observed and measured using Image J
software. The relative distance was calculated as a mean width of the cell scratch. Images were obtained at 4× magnification.
148 RhoC Mediates Head and Neck Cancer Progression Tumur et al. Neoplasia Vol. 17, No. 1, 2015so clear, however. Although a number of studies have implicated RhoA
in processes leading to transformation andmigration in cancer [31–33],
recent reports have shown that although excess RhoA can result in
cellular transformation, suppression of RhoA activity is essential for the
ability of tumor cells to migrate efficiently [29,34]. Our findings
support this idea in a couple of ways. First, out of the seven SCC cell
lines examined, four (UM-SCC-1, 5, and 6) demonstrated higher
RhoC expression relative to RhoA expression, whereas HOK cells,
despite expressing a somewhat high level of RhoC and RhoA protein
overall, expressed both GTPases in relatively equal proportions to one
another (Figure 3A). And second, RhoC and RhoA activation status
following 100 ng/ml of EGF stimulation differed between primary oral
keratinocytes and SCC cells. In UM-SCC-6 cells, both RhoA and
RhoC were immediately activated in as little as five minutes following
the addition of EGF (Figure 3C), whereas in HOK cells RhoA was
activated while RhoC remained unchanged (Figure 3B). These findings
suggest that not only do RhoA and RhoC have different expression
profiles and serve potentially different purposes in a given cell, but that
the two proteins might play different roles in malignant versus non-
malignant oral keratinocytes. Further studies will be necessary to more
comprehensively characterize these differences.
To our knowledge, this is the first report describing a specific role
for RhoC in HNSCC cell signaling that governs transcription of
E-cadherin and loss of cell-to-cell contact leading to tumor cell
migration and invasion. Despite an increasing number of reports
describing the relationship between RhoC overexpression and
prognostic outcomes across multiple tumor types, few studies have
explored the consequences and regulation of RhoC activation in
cancer and even fewer have explored the specific role it plays in
signaling pathways known to be important in HNSCC, like those
associated with EGFR and PI3K activation. For example, Bellovin et
al., 2006, identified RhoC as a prognostic marker of colon carcinoma
where they showed up-regulation of RhoC expression following
epithelial to mesenchymal transition, a process by which epithelialcells acquire mesenchymal features that promote tumor progression.
They went on to show that RhoC expression and activation correlated
with a loss of E-cadherin expression and enhanced cell migration.
Despite these compelling findings, RhoC expression and activation
were not shown to be directly linked to E-cadherin loss, making it
difficult to rule out the involvement of parallel pathways. In the
current study, we demonstrate that knock-down of RhoC results in a
return of E-cadherin expression (Figure 5B) and a reduction of in vitro
invasion and migration (Figure 6, A and B, respectively), supporting a
direct upstream role for RhoC in regulating E-cadherin expression.
Down-regulation of E-cadherin promotes tumor cell migration and
invasion by dismantling the cell-to-cell adhesion complex, resulting in
cell polarity loss and enhanced motility. Loss of E-cadherin as a tumor
progresses can occur as a result of both genetic and epigenetic
mechanisms; however cell signaling dysregulation serves as the primary
mechanism by which E-cadherin trafficking and transcription occur.
Specifically, initiation of cell signaling cascades leading to increased gene
expression of transcription factors that bind the E-cadherin promoter,
like the Snail superfamily, serves as one of the most well documented
mechanisms driving down-regulation of E-cadherin. Consistent with
these observations, we show that as Snail protein levels rise (Figure 2B)
following EGF stimulation, E-cadherin protein levels and membrane
localization are substantially reduced (Figure 5, A and C, respectively).
Although our data suggests transcriptional regulation of E-cadherin
in HNSCC, it is important to consider that control of E-cadherin
activity could also stem from posttranslational modifications,
including phosphorylation and ubiquitination of E-cadherin leading
to degradation [35,36]. For example, receptor tyrosine kinases, like
EGFR and fibroblast growth-factor receptor (FGFR), can directly
induce phosphorylation of E-cadherin, leading to disassembly of the
adhesion complex and disruption of the cadherin-mediated cell-to-
cell junctions [37]. Additionally, β-catenin plays a critical structural
role in cadherin-based adhesions and is involved in direct
transcriptional activation of the Slug gene, which encodes a
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Figure 7. Proposed model for RhoC-mediated EGFR signaling in the regulation of invasion in HNSCC.
Neoplasia Vol. 17, No. 1, 2015 RhoC Mediates Head and Neck Cancer Progression Tumur et al. 149transcriptional repressor of E-cadherin [38]. Recent studies in
colorectal cancer have demonstrated that Slug can be regulated by
PI3K/Akt/GSK-3β-mediated activation of β-catenin, leading to its
nuclear localization and subsequent transcriptional up-regulation of
Slug [39]. Moreover, studies have shown that EGFR interacts with
the cadherin–catenin complex, and upon ligand binding induces
tyrosine phosphorylation of β-catenin and disruption of cadherin-
catenin binding [40]. Next steps in our laboratory will begin to
decipher the impact these important competing pathways have on
E-cadherin loss in HNSCC, and the potential role RhoC plays in
mediating these signaling cascades.
Accumulating evidence indicates that the EGFR family and its
downstream signaling pathways, such as PI3K-Akt and MAPK
pathways, up-regulate Snail leading to underexpression of E-cadherin
[41,42]. Similarly, our results in HNSCC show clear activation of
PI3K/Akt/GSK-3β and ERK following EGFR phosphorylation
(Figure 2C). Activation of PI3K-Akt and subsequent phosphorylation
of GSK-3β is significant here as a wealth of literature exists, across
multiple tumor types, confirming the importance of GSK-3β
phosphorylation in stabilizing Snail so that it can translocate to
nucleus and participate in transcriptional regulation. However, a
variety of signaling cascades, in addition to the PI3K-Akt pathway,
have been shown to phosphorylate GSK-3β [43]. To rule out the
possibility of a parallel pathway bypassing the EGFR/PI3K/AKT
cascade, we employed a well-known PI3K inhibitor, Ly294002, and
looked at the effects it had on GSK-3β ser9 phosphorylation. As shown
in Figure 2D, GSK-3β ser9 phosphorylation was reduced upon PI3K-
Akt inhibition, supporting our hypothesis that PI3K-Akt plays a
significant role in GSK-3β ser9 regulation in these cells. Furthermore,
in RhoC knock-down experiments, Akt and GSK-3β phosphoryla-
tion was abrogated whereas ERK phosphorylation was not
(Figure 4B), suggesting a mediating role for RhoC in EGFR-PI3K
signaling but not in the EGFR-MAPK pathway.In our study, we observed a dose-dependent effect of EGF on
EGFR phosphorylation at Tyr992. In HNSCC cells, EGFRTyr992
phosphorylation was seen at EGF concentrations as low as 1.0 ng/ml.
In contrast, in HOK cells EGFRTyr992 phosphorylation was not seen
until EGF concentrations exceeded 10 mg/ml. These results are in
agreement with reports that EGF is a multifunctional cytokine that
elicits different and even opposite cellular responses between cell
types, and can even have different effects within the same cell type,
depending on concentration [26,44,45]. Based on these findings, one
might speculate that perhaps these differences in EGFR responsive-
ness according to EGF concentration might help us to understand
how EGF availability in the oral cavity contributes to tumorigenesis
and metastasis in HNSCC. For example, the physiologic concentra-
tion of EGF in whole saliva has been shown to be around 1 ng/ml and
this concentration has an ability to promote oral epithelial cell
chemotaxis [46,47]. Given that we observed significantly different
responses to lower concentrations of EGF in HNSCC versus HOK,
perhaps acquisition of EGF responsiveness might be an important
step in HNSCC tumor development.
Conclusions
In this study we provide important insights into the molecular
mechanismsmediating the EGF-induced down-regulation of E-cadherin
leading to increased cell invasion in HNSCC. Ours is the first report
demonstrating that activation of RhoC signaling, following EGFR
phosphorylation, likely plays a significant role in down-regulation of cell
surface E-cadherin in HNSCC. Specifically, activated RhoC, acting via
PI3K signaling, stabilizes Snail and down-regulates E-cadherin, which
contributes to EGF-induced cell invasion (Figure 7). Our data, taken
together with an emergence of literature elucidating the role of Rho
family members in tumor metastasis, argue that RhoC is a promising
target in the development of novel strategies aimed at halting head and
neck cancer progression.
150 RhoC Mediates Head and Neck Cancer Progression Tumur et al. Neoplasia Vol. 17, No. 1, 2015Acknowledgements
We would like to thank Dr. Thomas Carey for the provision of
UM-SCC cell lines and the Western University of Health Sciences
College of Osteopathic Medicine of the Pacific and College Dental
Medicine for providing financial support for the project.
References
[1] Howlader N, N. A, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL,
Yu M, Ruhl J, and Tatalovich Z, et al (2014). SEER Cancer Statistics Review,
1975–2011. National Cancer Institute; 2014.
[2] Clark EA, Golub TR, Lander ES, and Hynes RO (2000). Genomic analysis of
metastasis reveals an essential role for RhoC. Nature 406, 532–535.
[3] van Golen KL, Wu ZF, Qiao XT, Bao LW, and Merajver SD (2000). RhoC
GTPase, a novel transforming oncogene for human mammary epithelial cells that
partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 60,
5832–5838.
[4] Suwa H, Ohshio G, Imamura T, Watanabe G, Arii S, Imamura M, Narumiya S,
Hiai H, and Fukumoto M (1998). Overexpression of the rhoC gene correlates
with progression of ductal adenocarcinoma of the pancreas. Br J Cancer 77,
147–152.
[5] Khosravi-Far R, Solski PA, Clark GJ, Kinch MS, and Der CJ (1995). Activation
of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras
transformation. Mol Cell Biol 15, 6443–6453.
[6] Michiels F, Habets GG, Stam JC, van der Kammen RA, and Collard JG (1995).
A role for Rac in Tiam1-induced membrane ruffling and invasion. Nature 375,
338–340.
[7] Habets GG, Scholtes EH, Zuydgeest D, van der Kammen RA, Stam JC, Berns A,
and Collard JG (1994). Identification of an invasion-inducing gene, Tiam-1, that
encodes a protein with homology to GDP-GTP exchangers for Rho-like proteins.
Cell 77, 537–549.
[8] Keely PJ, Westwick JK, Whitehead IP, Der CJ, and Parise LV (1997). Cdc42
and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)
K. Nature 390, 632–636.
[9] Hynes RO and Zhao Q (2000). The evolution of cell adhesion. J Cell Biol 150,
F89–F96.
[10] IslamM, Lin G, Brenner JC, Pan Q, Merajver SD, Hou Y, Kumar P, and Teknos
TN (2009). RhoC expression and head and neck cancer metastasis. Mol Cancer
Res 7, 1771–1780.
[11] Islam M, Sharma S, and Teknos TN (2014). RhoC regulates cancer stem cells in
head and neck squamous cell carcinoma by overexpressing IL-6 and
phosphorylation of STAT3. PLoS One 9, e88527.
[12] Nicholson RI, Gee JM, and Harper ME (2001). EGFR and cancer prognosis.
Eur J Cancer 37(Suppl. 4), S9–S15.
[13] Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, and
Milas L (2002). Impact of epidermal growth factor receptor expression on
survival and pattern of relapse in patients with advanced head and neck
carcinoma. Cancer Res 62, 7350–7356.
[14] Bussink J, van der Kogel AJ, and Kaanders JH (2008). Activation of the PI3-K/
AKT pathway and implications for radioresistance mechanisms in head and neck
cancer. Lancet Oncol 9, 288–296.
[15] Matta A and Ralhan R (2009). Overview of current and future biologically based
targeted therapies in head and neck squamous cell carcinoma. Head Neck Oncol
1, 6.
[16] Cheng JC, Chang HM, and Leung PC (2012). Epidermal growth factor induces
human oviductal epithelial cell invasion by down-regulating E-cadherin
expression. J Clin Endocrinol Metab 97, E1380-1389.
[17] Forastiere AA and Burtness BA (2007). Epidermal growth factor receptor
inhibition in head and neck cancer–more insights, but more questions. J Clin
Oncol 25, 2152–2155.
[18] Lo HW, Xia W, Wei Y, Ali-Seyed M, Huang SF, and Hung MC (2005). Novel
prognostic value of nuclear epidermal growth factor receptor in breast cancer.
Cancer Res 65, 338–348.
[19] Sharafinski ME, Ferris RL, Ferrone S, and Grandis JR (2010). Epidermal growth
factor receptor targeted therapy of squamous cell carcinoma of the head and neck.
Head neck 32, 1412–1421.
[20] Emlet DR, Moscatello DK, Ludlow LB, and Wong AJ (1997). Subsets of
epidermal growth factor receptors during activation and endocytosis. J Biol Chem
272, 4079–4086.[21] Holbrook MR, O'Donnell Jr JB, Slakey LL, and Gross DJ (1999). Epidermal
growth factor receptor internalization rate is regulated by negative charges near
the SH2 binding site Tyr992. Biochemistry 38, 9348–9356.
[22] Guo L, Kozlosky CJ, Ericsson LH, Daniel TO, Cerretti DP, and Johnson RS
(2003). Studies of ligand-induced site-specific phosphorylation of epidermal
growth factor receptor. J Am Soc Mass Spectrom 14, 1022–1031.
[23] Xiao D and He J (2010). Epithelial mesenchymal transition and lung cancer.
J Thorac Dis 2, 154–159.
[24] Wheeler AP and Ridley AJ (2004). Why three Rho proteins? RhoA, RhoB,
RhoC, and cell motility. Exp Cell Res 301, 43–49.
[25] Jaffe AB and Hall A (2005). Rho GTPases: biochemistry and biology. Annu Rev
Cell Dev Biol 21, 247–269.
[26] Han J, Li L, Hu J, Yu L, Zheng Y, Guo J, Zheng X, Yi P, and Zhou Y (2010).
Epidermal growth factor stimulates human trophoblast cell migration through
Rho A and Rho C activation. Endocrinology 151, 1732–1742.
[27] van Golen KL, Davies S, Wu ZF, Wang Y, Bucana CD, Root H,
Chandrasekharappa S, Strawderman M, Ethier SP, and Merajver SD (1999).
A novel putative low-affinity insulin-like growth factor-binding protein, LIBC
(lost in inflammatory breast cancer), and RhoC GTPase correlate with the
inflammatory breast cancer phenotype. Clin Cancer Res 5, 2511–2519.
[28] Shikada Y, Yoshino I, Okamoto T, Fukuyama S, Kameyama T, and Maehara Y
(2003). Higher expression of RhoC is related to invasiveness in non-small cell
lung carcinoma. Clin Cancer Res 9, 5282–5286.
[29] Bellovin DI, Simpson KJ, Danilov T, Maynard E, Rimm DL, Oettgen P, and
Mercurio AM (2006). Reciprocal regulation of RhoA and RhoC characterizes the
EMT and identifies RhoC as a prognostic marker of colon carcinoma. Oncogene
25, 6959–6967.
[30] Hakem A, Sanchez-Sweatman O, You-Ten A, Duncan G, Wakeham A, Khokha
R, and Mak TW (2005). RhoC is dispensable for embryogenesis and tumor
initiation but essential for metastasis. Genes Dev 19, 1974–1979.
[31] Li B, Antonyak MA, Zhang J, and Cerione RA (2012). RhoA triggers a specific
signaling pathway that generates transforming microvesicles in cancer cells.
Oncogene 31, 4740–4749.
[32] Giang Ho TT, Stultiens A, Dubail J, Lapiere CM, Nusgens BV, Colige AC, and
Deroanne CF (2011). RhoGDIalpha-dependent balance between RhoA and
RhoC is a key regulator of cancer cell tumorigenesis.Mol Biol Cell 22, 3263–3275.
[33] Chen YS, HuangWL, Chang SH, Chang KW, Kao SY, Lo JF, and Su PF (2013).
Enhanced filopodium formation and stem-like phenotypes in a novel metastatic
head and neck cancer cell model. Oncol Rep 30, 2829–2837.
[34] Bellovin DI, Bates RC, Muzikansky A, Rimm DL, and Mercurio AM (2005).
Altered localization of p120 catenin during epithelial to mesenchymal transition
of colon carcinoma is prognostic for aggressive disease. Cancer Res 65,
10938–10945.
[35] Swaminathan G and Cartwright CA (2012). Rack1 promotes epithelial cell-cell
adhesion by regulating E-cadherin endocytosis. Oncogene 31, 376–389.
[36] Delva E and Kowalczyk AP (2009). Regulation of cadherin trafficking. Traffic
10, 259–267.
[37] Cavallaro U and Christofori G (2004). Cell adhesion and signalling by cadherins
and Ig-CAMs in cancer. Nat Rev Cancer 4, 118–132.
[38] Conacci-SorrellM, Simcha I, Ben-Yedidia T, Blechman J, Savagner P, andBen-Ze'ev
A (2003). Autoregulation of E-cadherin expression by cadherin-cadherin interactions:
the roles of beta-catenin signaling, Slug, and MAPK. J Cell Biol 163, 847–857.
[39] Suman S, Kurisetty V, Das TP, Vadodkar A, Ramos G, Lakshmanaswamy R, and
Damodaran C (2014). Activation of AKT signaling promotes epithelial-
mesenchymal transition and tumor growth in colorectal cancer cells. Mol
Carcinog 53(Suppl. 1), E151-160.
[40] Hoschuetzky H, Aberle H, and Kemler R (1994). Beta-catenin mediates the
interaction of the cadherin-catenin complex with epidermal growth factor
receptor. J Cell Biol 127, 1375–1380.
[41] Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, and HungMC (2004). Dual
regulation of Snail by GSK-3beta-mediated phosphorylation in control of
epithelial-mesenchymal transition. Nat Cell Biol 6, 931–940.
[42] Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, van Roy F, Lee-Kwon W,
Donowitz M, Tsichlis PN, and Larue L (2003). The protein kinase Akt induces
epithelial mesenchymal transition and promotes enhanced motility and
invasiveness of squamous cell carcinoma lines. Cancer Res 63, 2172–2178.
[43] Zheng H, Li W, Wang Y, Liu Z, Cai Y, Xie T, Shi M, Wang Z, and Jiang B
(2013). Glycogen synthase kinase-3 beta regulates Snail and beta-catenin
expression during Fas-induced epithelial-mesenchymal transition in gastrointes-
tinal cancer. Eur J Cancer 49, 2734–2746.
Neoplasia Vol. 17, No. 1, 2015 RhoC Mediates Head and Neck Cancer Progression Tumur et al. 151[44] Staun-Ram E, Goldman S, Gabarin D, and Shalev E (2004). Expression and
importance of matrix metalloproteinase 2 and 9 (MMP-2 and −9) in human
trophoblast invasion. Reprod Biol Endocrinol 2, 59.
[45] Maheshwari G, Wells A, Griffith LG, and Lauffenburger DA (1999). Biophysical
integration of effects of epidermal growth factor and fibronectin on fibroblast
migration. Biophys J 76, 2814–2823.[46] Royce LS and Baum BJ (1991). Physiologic levels of salivary epidermal growth
factor stimulate migration of an oral epithelial cell line. Biochim Biophys Acta
1092, 401–403.
[47] Ohshima M, Sato M, Ishikawa M, Maeno M, and Otsuka K (2002). Physiologic
levels of epidermal growth factor in saliva stimulate cell migration of an oral
epithelial cell line, HO-1-N-1. Eur J Oral Sci 110, 130–136.
